AI-generated from publicly available materials.Hanmi Pharmaceutical has announced a strategic partnership with FuriosaAI to transition its Digital Healthcare platform's AI infrastructure from an overseas cloud to a domestic setup in South Korea. This move aims to enhance data management and operational stability by utilizing local technologies for its large language model (LLM) and AI semiconductor.
On the 30th of last month, Hanmi signed an agreement with FuriosaAI, Xperix, and Bagle Labs to adapt the Epiday chatbot to a Korean-style LLM. This initiative will enable the AI health coaching function of the Digital Healthcare platform to operate on local servers, which is a key focus for Hanmi. The transition is expected to improve the chatbot's performance by shifting its answer-generation capabilities from foreign cloud services to domestic infrastructure.
Epiday offers personalized health management by allowing users to log their health data and receive tailored advice, particularly for obesity treatment. Hanmi plans to leverage the health information gathered through this service to enhance its features related to lifestyle habit management. The company will first convert the AI coaching function and subsequently integrate local models for other features like drug and diet searches.
Under this partnership, Hanmi will lead the project direction, while Bagle Labs will develop the Epiday app and chatbot. Xperix will manage the infrastructure for domestic AI servers, and FuriosaAI will supply the necessary semiconductor technology. The companies have already conducted initial tests to ensure the domestic system can match or exceed the performance of the previous setup, with plans for further quality verification before a full rollout. This collaboration signifies a significant step towards localizing digital health technologies in Korea, potentially paving the way for broader applications in the healthcare sector.